Show simple item record

dc.contributor.authorKumra, Sanjiv
dc.contributor.authorFrazier, Jean A.
dc.contributor.authorJacobsen, Leslie K.
dc.contributor.authorMcKenna, Kathleen
dc.contributor.authorGordon, Charles T.
dc.contributor.authorLenane, Marge C.
dc.contributor.authorHamburger, Susan D.
dc.contributor.authorSmith, A. K.
dc.contributor.authorAlbus, K. E.
dc.contributor.authorAlaghband-Rad, Javad
dc.contributor.authorRapoport, Judith L.
dc.date2022-08-11T08:10:27.000
dc.date.accessioned2022-08-23T17:09:50Z
dc.date.available2022-08-23T17:09:50Z
dc.date.issued1996-12-01
dc.date.submitted2011-02-11
dc.identifier.citationArch Gen Psychiatry. 1996 Dec;53(12):1090-7.
dc.identifier.issn0003-990X (Linking)
dc.identifier.pmid8956674
dc.identifier.urihttp://hdl.handle.net/20.500.14038/45911
dc.description.abstractBACKGROUND: Childhood-onset schizophrenia is a rare but severe form of the disorder that is often treatment-refractory. In this study, the efficacy and adverse effects of clozapine and haloperidol were compared for children and adolescents with early-onset schizophrenia. METHODS: Twenty-one patients (mean [+/-SD] age, 14.0 +/- 2.3 years) with onset of Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition-defined schizophrenia that began by age 12 years and who had been nonresponsive to typical neuroleptics participated in the study. Patients were randomized to a 6-week double-blind parallel comparison of clozapine (mean [+/-SD] final dose, 176 +/- 149 mg/d), or haloperidol, (16 +/- 8 mg/d). RESULTS: Clozapine was superior to haloperidol on all measures of psychosis (P = .04-.002). Positive and negative symptoms of schizophrenia improved. However, neutropenia and seizures were major concerns. To date, one third of the group has discontinued using clozapine. CONCLUSIONS: Clozapine has striking superiority for positive and negative symptoms in treatment-refractory childhood-onset schizophrenia. However, due to possibly increased toxic effects in this pediatric population, close monitoring for adverse events is essential.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=8956674&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://archpsyc.ama-assn.org/cgi/reprint/53/12/1090
dc.subjectAdolescent
dc.subjectAge Factors
dc.subjectAge of Onset
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectClozapine
dc.subjectDouble-Blind Method
dc.subjectDrug Administration Schedule
dc.subjectHaloperidol
dc.subjectHumans
dc.subjectNeutropenia
dc.subjectPsychiatric Status Rating Scales
dc.subjectSchizophrenia, Childhood
dc.subjectSeizures
dc.subjectSeverity of Illness Index
dc.subjectTreatment Outcome
dc.subjectPsychiatry
dc.titleChildhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison
dc.typeJournal Article
dc.source.journaltitleArchives of general psychiatry
dc.source.volume53
dc.source.issue12
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/psych_pp/437
dc.identifier.contextkey1779642
html.description.abstract<p>BACKGROUND: Childhood-onset schizophrenia is a rare but severe form of the disorder that is often treatment-refractory. In this study, the efficacy and adverse effects of clozapine and haloperidol were compared for children and adolescents with early-onset schizophrenia.</p> <p>METHODS: Twenty-one patients (mean [+/-SD] age, 14.0 +/- 2.3 years) with onset of Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition-defined schizophrenia that began by age 12 years and who had been nonresponsive to typical neuroleptics participated in the study. Patients were randomized to a 6-week double-blind parallel comparison of clozapine (mean [+/-SD] final dose, 176 +/- 149 mg/d), or haloperidol, (16 +/- 8 mg/d).</p> <p>RESULTS: Clozapine was superior to haloperidol on all measures of psychosis (P = .04-.002). Positive and negative symptoms of schizophrenia improved. However, neutropenia and seizures were major concerns. To date, one third of the group has discontinued using clozapine.</p> <p>CONCLUSIONS: Clozapine has striking superiority for positive and negative symptoms in treatment-refractory childhood-onset schizophrenia. However, due to possibly increased toxic effects in this pediatric population, close monitoring for adverse events is essential.</p>
dc.identifier.submissionpathpsych_pp/437
dc.contributor.departmentDepartment of Psychiatry
dc.source.pages1090-7


This item appears in the following Collection(s)

Show simple item record